Patent · US Active

Lassa virus vaccine

US12161711B2 · kind B2 · utility

0Cited by

114References

14Claims

0Family size

Assignee

CureVac SE · DE

Inventors

Edith JASNY · Stuttgart, DE
Benjamin PETSCH · Tübingen, DE

Key dates

Filing date	Sep 6, 2022
Grant date	Dec 10, 2024
Priority date	—
Expiry date	Sep 6, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides mRNAs usable as vaccines against lassa virus (LASV) infections. Further, the Invention relates to (pharmaceutical) compositions and vaccines comprising said mRNAs and their use for treatment or prophylaxis of a lassa virus infection. The present invention further features a kit comprising the mRNAs, (pharmaceutical) compositions or vaccines and a method for treatment or prophylaxis of lassa virus infections using said mRNAs, (pharmaceutical) compositions or vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.